Equity alert: the rosen law firm announces investigation of securities claims against acelrx pharmaceuticals, inc. – acrx

New york--(business wire)--the rosen law firm, p.a., a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of acelrx pharmaceuticals, inc. (nasdaq: acrx) resulting from allegations that acelrx may have issued materially misleading business information to the investing public. on march 9, 2015, the company announced that last week it had received correspondence from the food and drug administration (“fda”) stating that in addition to the bench testing and two human factors studies that have already been performed, an additional clinical study is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. on this news, shares of acelrx fell over 1/3 during intraday trading on march 9, 2015. the rosen law firm is preparing a class action lawsuit to recover losses suffered by acelrx investors. if you purchased shares of acelrx before march 9, 2015, please visit the website at http://rosenlegal.com/cases-538.html for more information. you may also contact phillip kim, esq. or kevin chan, esq. of the rosen law firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com. the rosen law firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. attorney advertising. prior results do not guarantee a similar outcome.
ACRX Ratings Summary
ACRX Quant Ranking